癌症生物标记市场规模、份额、成长分析（按分析技术、按癌症类型、按产品、按应用、按最终用户、按地区）—2025 年至 2032 年行业预测

2023 年癌症生物标记市场规模价值 271 亿美元，预计将从 2024 年的 304.9 亿美元增长到 2032 年的 782.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 12.5%。

受全球癌症发生率上升和肿瘤学研究投入增加的推动，全球癌症生物标记市场预计将显着增长。人们越来越意识到癌症生物标记在提高诊断准确性和治疗效果方面的关键作用，并有望为该领域的公司开闢新的途径。此外，个人化医疗和基因治疗的日益增长的趋势预计将进一步促进癌症生物标记的使用。技术进步，加上对非侵入性和微创方法的偏好，可能会创造更多的机会。然而，对临床有效性的担忧、医疗保健专业人员的认识有限、道德问题以及严格的监管环境等挑战可能会在未来几年限制市场的发展。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

癌症生物标记市场规模（依分析技术及复合年增长率） (2025-2032)

• 市场概览
• 体学技术
  • 蛋白质体学
  • 免疫检测
  • 质谱法
  • 二维凝胶电泳
  • 蛋白质微阵列
  • 其他的
  • 基因组学
  • 次世代定序
  • 聚合酵素链锁反应
  • 原位杂交
  • 其他的
• 影像技术
  • 超音波影像
  • 电脑断层扫描
  • 磁振造影
  • 正子断层扫描
  • 乳房X光检查

癌症生物标记市场规模（按癌症类型和复合年增长率） (2025-2032)

• 市场概览
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 黑色素瘤
• 白血病
• 甲状腺癌
• 膀胱癌
• 非何杰金氏淋巴瘤
• 肾癌
• 其他的

癌症生物标记市场规模（按产品和复合年增长率） (2025-2032)

• 市场概览
• 装置
  • 影像设备
  • 基于病理学的设备
  • 切片检查器械
• 耗材
  • 抗体
  • 套件和试剂
  • 探测
• 生物资讯软体

癌症生物标记市场规模（按应用）及复合年增长率（2025-2032）

• 市场概览
• 诊断
• 研究与开发
• 预后
• 风险评估
• 其他用途

癌症生物标记市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 诊断实验室
• 与生物製药公司的交叉关係
• 研究和学术机构
• 其他的

癌症生物标记市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• F. Hoffmann-La Roche AG（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• QIAGEN NV（Germany/Netherlands）
• Agilent Technologies, Inc.（USA）
• Abbott Laboratories（USA）
• Illumina, Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• Myriad Genetics, Inc.（USA）
• Guardant Health, Inc.（USA）
• Exact Sciences Corporation（USA）
• Sysmex Corporation（Japan）
• Danaher Corporation（USA）
• PerkinElmer, Inc.（USA）
• DiaSorin SpA（Italy）
• BioMerieux SA（France）
• Natera, Inc.（USA）
• Adaptive Biotechnologies Corporation（USA）
• NeoGenomics, Inc.（USA）

结论和建议

Cancer Biomarkers Market size was valued at USD 27.1 billion in 2023 and is poised to grow from USD 30.49 billion in 2024 to USD 78.22 billion by 2032, growing at a CAGR of 12.5% during the forecast period (2025-2032).

The global cancer biomarker market is poised for significant growth, driven by an increasing incidence of cancer worldwide and heightened investments in oncology research. Growing awareness of the critical role of cancer biomarkers in enhancing diagnostic accuracy and treatment efficacy is expected to open new avenues for companies in this sector. Additionally, the rising trend of personalized medicine and gene therapies is anticipated to further propel the utilization of cancer biomarkers. Technological advancements coupled with a preference for non-invasive and minimally invasive methods will create further opportunities. However, challenges such as concerns over clinical validity, limited awareness among healthcare professionals, ethical issues, and stringent regulatory landscapes could constrain market progress in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Biomarkers Market Segments Analysis

Global Cancer Biomarkers Market is segmented by Profiling Technology, Cancer Type, Product, Application, End User and region. Based on Profiling Technology, the market is segmented into Omics Technology and Imaging Technologies. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkins Lymphoma, Kidney Cancer and Others. Based on Product, the market is segmented into Instruments, Consumables and Bioinformatics Software. Based on Application, the market is segmented into Diagnostics, Research and Development, Prognostics, Risk Assessment and Other Applications. Based on End User, the market is segmented into Diagnostic Laboratories, Biopharmaceutical Companies and Cros, Research and Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Biomarkers Market

The rising prevalence of cancer is largely attributed to poor lifestyle choices and the widespread adoption of unhealthy habits, leading to a significant increase in the number of individuals diagnosed with the disease. This alarming trend is a primary driver for the cancer biomarkers market, as these biomarkers are essential for both cancer diagnosis and treatment. Their critical function in identifying cancer early and facilitating targeted therapies has amplified the demand for cancer biomarkers globally, reflecting the urgent need for effective diagnostic tools and treatment options in the growing battle against cancer.

Restraints in the Cancer Biomarkers Market

The Cancer Biomarkers market faces significant challenges, primarily due to concerns surrounding the privacy and ethical use of the molecular and genetic data from patients. Since cancer biomarkers provide insights that go beyond mere identification, they carry sensitive information about an individual's health. As public awareness and apprehension regarding data privacy rise, it is likely to inhibit the growth and demand for cancer biomarkers in the near future. Companies operating in this sector must navigate these issues carefully to maintain trust and foster adoption while ensuring compliance with evolving regulations related to personal health information.

Market Trends of the Cancer Biomarkers Market

The Cancer Biomarkers market is witnessing a significant trend towards the integration of artificial intelligence (AI) and machine learning technologies, revolutionizing biomarker research and diagnostics. Companies are leveraging AI to analyze extensive datasets, enabling them to uncover intricate patterns that facilitate the rapid discovery of novel cancer biomarkers. This technological advancement not only accelerates innovation but also enhances diagnostic accuracy, which is crucial for personalized medicine. As stakeholders increasingly recognize the potential of AI-driven insights, investment in these advanced technologies is expected to rise, positioning AI as a pivotal component in the advancement of cancer biomarker research and clinical applications.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Cancer Biomarkers Market Size by Profiling Technology & CAGR (2025-2032)

• Market Overview
• Omics Technology
  • Proteomics
  • Immunoassays
  • Mass Spectrometry
  • 2D gel Electrophoresis
  • Protein Microarrays
  • Others
  • Genomics
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • In Situ Hybridization
  • Others
• Imaging Technologies
  • Ultrasound Imaging
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Mammography

Global Cancer Biomarkers Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Leukemia
• Thyroid Cancer
• Bladder Cancer
• Non-Hodgkins Lymphoma
• Kidney Cancer
• Others

Global Cancer Biomarkers Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
  • Imaging Instruments
  • Pathology Based Instruments
  • Biopsy Instruments
• Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
• Bioinformatics Software

Global Cancer Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
• Research and Development
• Prognostics
• Risk Assessment
• Other Applications

Global Cancer Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic Laboratories
• Biopharmaceutical Companies and Cros
• Research and Academic Institutes
• Others

Global Cancer Biomarkers Market Size & CAGR (2025-2032)

• North America (Profiling Technology, Cancer Type, Product, Application, End User)
  • US
  • Canada
• Europe (Profiling Technology, Cancer Type, Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Profiling Technology, Cancer Type, Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Profiling Technology, Cancer Type, Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Profiling Technology, Cancer Type, Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Germany/Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations